{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:51:43Z","timestamp":1762865503932},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.diagmicrobio.2009.02.002","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T09:21:07Z","timestamp":1235726467000},"page":"415-425","source":"Crossref","is-referenced-by-count":18,"title":["Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents"],"prefix":"10.1016","volume":"63","author":[{"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Turnidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.mib.2006.08.011","article-title":"The CTX-M \u03b2-lactamase pandemic","volume":"9","author":"Canton","year":"2006","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/AAC.01114-07","article-title":"Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-\u03b2-lactamase\u2013producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program","volume":"52","author":"Castanheira","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib4","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard\u2014seventh edition, M7-A7","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib5","series-title":"Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib6","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1128\/JCM.34.8.1880-1884.1996","article-title":"Detection of extended-spectrum \u03b2-lactamase (ESBL)-producing strains by the Etest ESBL screen","volume":"34","author":"Cormican","year":"1996","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib7","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/AAC.01529-07","article-title":"Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa","volume":"52","author":"Davies","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib8","series-title":"Doribax\u2122 product package insert","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib10","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/AAC.48.4.1384-1396.2004","article-title":"In vitro antimicrobial activity of doripenem, a new carbapenem","volume":"48","author":"Ge","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1469-0691.2007.01855.x","article-title":"Prevalence and clonality of extended-spectrum \u03b2-lactamases in Asia","volume":"14","author":"Hawkey","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","article-title":"Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with \u03b2-lactam antibiotics","volume":"222","author":"Horiuchi","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/dkh298","article-title":"Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations","volume":"54","author":"Jones","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various \u03b2-lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2008.01.017","article-title":"Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance","volume":"61","author":"Jones","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","author":"Livermore","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib17","first-page":"41","article-title":"Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06","volume":"62","author":"Livermore","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized \u03b2-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib20","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjmed.2006.03.013","article-title":"esistance in Gram-negative bacteria: Enterobacteriaceae","volume":"119","author":"Paterson","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.coph.2007.08.003","article-title":"The continuing challenge of ESBLs","volume":"7","author":"Perez","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib22","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1128\/AAC.00381-08","article-title":"In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States","volume":"52","author":"Pillar","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jac\/dki166","article-title":"Emergence of Enterobacteriaceae producing extended-spectrum \u03b2-lactamase (ESBLs) in the community","volume":"56","author":"Pitout","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib25","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"Rea-Neto","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0732-8893(03)00052-X","article-title":"Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"47","author":"Sader","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ja.2006.31","article-title":"Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem","volume":"59","author":"Sakyo","year":"2006","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib28","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/AAC.00464-08","article-title":"Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation","volume":"52","author":"Tanimoto","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.42.1.94","article-title":"In vitro and in vivo antibacterial activities of S-4661, a new carbapenem","volume":"42","author":"Tsuji","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QCO.0b013e328303670b","article-title":"Clinically significant carbapenemases: an update","volume":"21","author":"Walsh","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2009.02.002_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309000571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889309000571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T05:49:54Z","timestamp":1589608194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889309000571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0732889309000571"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2009.02.002","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}